72 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
discovery to identify new product candidates across various targets including pain and seizure disorders. With a strong balance sheet to support our … targets and develop new product candidates. The near-term focus is on development candidates targeting Kv7, Nav1.1 and Nav1.7, and Xenon expects
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
of being produced in commercial quantities at an acceptable cost, or at all.
If our discovery activities fail to identify novel targets for drug discovery … , or such targets prove to be unsuitable for treating human disease, or if we are unable to develop product candidates with specificity
424B5
hcgldox22e
29 Nov 23
Prospectus supplement for primary offering
5:05pm
424B5
aco f98qev
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
yfoo8xa7fvnujox5
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
4rj33xlbp5g7uty
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
ownv0
6 Oct 21
Prospectus supplement for primary offering
5:05pm
424B5
d463rbl
4 Oct 21
Prospectus supplement for primary offering
5:27pm